(Q34665858)

3 August 2017

title

Effects of olanzapine and ziprasidone on glucose tolerance in healthy volunteers (English)

1 reference

3 August 2017

10

Siegfried Kasper

0 references

Nilufar Mossaheb

object named as

Nilufar Mossaheb

2

0 references

Julia Sacher

object named as

Julia Sacher

1

0 references

author name string

Christoph Spindelegger

3

1 reference

3 August 2017

Nikolas Klein

4

1 reference

3 August 2017

Thomas Geiss-Granadia

5

1 reference

3 August 2017

Robert Sauermann

6

1 reference

3 August 2017

Edith Lackner

7

1 reference

3 August 2017

Christian Joukhadar

8

1 reference

3 August 2017

Markus Müller

9

1 reference

3 August 2017

language of work or name

English

0 references

publication date

22 August 2007

1 reference

3 August 2017

published in

Neuropsychopharmacology

1 reference

3 August 2017

volume

33

1 reference

3 August 2017

issue

7

1 reference

3 August 2017

page(s)

1633-1641

1 reference

Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301541

Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301541

Prevalence and correlates of diabetes in national schizophrenia samples.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301541

Olanzapine versus haloperidol treatment in first-episode psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301541

Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301541

7 January 2021

Consensus development conference on antipsychotic drugs and obesity and diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301541

7 January 2021

Atypical antipsychotics and glucose homeostasis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301541

7 January 2021

Consensus development conference on antipsychotic drugs and obesity and diabetes: response to consensus statement

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301541

7 January 2021

Hyperglycemia and diabetes in patients with schizophrenia or schizoaffective disorders.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301541

7 January 2021

Metabolic abnormalities associated with second generation antipsychotics: fact or fiction? Development of guidelines for screening and monitoring

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301541

7 January 2021

Advancing the treatment of people with mental illness: a call to action in the management of metabolic issues

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301541

7 January 2021

Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301541

7 January 2021

Differential metabolic effects of antipsychotic treatments

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301541

7 January 2021

Abnormalities in glucose regulation associated with mental illness and treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301541

7 January 2021

Glucose intolerance with atypical antipsychotics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301541

7 January 2021

Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301541

7 January 2021

Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301541

7 January 2021

Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301541

7 January 2021

Glycerol production in subcutaneous adipose tissue in lean and obese humans

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301541

7 January 2021

Metabolic effects of treatment with atypical antipsychotics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301541

7 January 2021

Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301541

7 January 2021

Insulin sensitivity and abdominal obesity in African-American, Hispanic, and non-Hispanic white men and women. The Insulin Resistance and Atherosclerosis Study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301541

7 January 2021

Risperidone olanzapine drug outcomes studies in schizophrenia (RODOS): efficacy and tolerability results of an international naturalistic study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301541

7 January 2021

From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301541

7 January 2021

Olanzapine-associated diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301541

7 January 2021

Differential efficacy of olanzapine for deficit and nondeficit negative symptoms in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301541

7 January 2021

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301541

7 January 2021

Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301541

7 January 2021

Visceral adipose tissue impairs insulin secretion and insulin sensitivity but not energy expenditure in obesity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301541

7 January 2021

Clinical outcome and olanzapine plasma levels in acute schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301541

7 January 2021

Dietary fat and insulin sensitivity in a triethnic population: the role of obesity. The Insulin Resistance Atherosclerosis Study (IRAS)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301541

7 January 2021

The metabolic syndrome and schizophrenia: a review

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301541

7 January 2021

The continuing epidemics of obesity and diabetes in the United States

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301541

7 January 2021

Diabetes mellitus in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301541

7 January 2021

Science, medicine, and the future: Microdialysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301541

7 January 2021

Application of microdialysis to clinical pharmacokinetics in humans

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301541

7 January 2021

Metabolic risk during antipsychotic treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301541

7 January 2021

Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301541

7 January 2021

Insulin resistance in patients with depression and its changes during the clinical course of depression: minimal model analysis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301541

7 January 2021

Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301541

7 January 2021

Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301541

7 January 2021

Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301541

7 January 2021

Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301541

7 January 2021

Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301541

7 January 2021

Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301541

7 January 2021

Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301541

7 January 2021

Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis, and antilipolysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301541

7 January 2021

Minimal model analysis of intravenous glucose tolerance test-derived insulin sensitivity in diabetic subjects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301541

7 January 2021

New-onset diabetes and ketoacidosis with atypical antipsychotics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301541

7 January 2021

Identifiers

DOI

10.1038/SJ.NPP.1301541

1 reference

Dimensions Publication ID

3 August 2017

1020857937

0 references

1 reference